Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Palatin Technologies (PTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,786
  • Shares Outstanding, K 198,680
  • Annual Sales, $ 44,720 K
  • Annual Income, $ -13,330 K
  • 36-Month Beta 1.69
  • Price/Sales 4.13
  • Price/Cash Flow N/A
  • Price/Book 18.66
  • Price/Earnings ttm 7.15
  • Earnings Per Share ttm 0.13
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/15/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.87 +7.92%
on 06/19/18
1.28 -26.56%
on 06/04/18
-0.22 (-18.97%)
since 05/21/18
3-Month
0.87 +7.92%
on 06/19/18
1.59 -40.88%
on 04/10/18
-0.18 (-16.07%)
since 03/21/18
52-Week
0.36 +161.11%
on 06/22/17
1.59 -40.88%
on 04/10/18
+0.58 (+161.11%)
since 06/21/17

Most Recent Stories

More News
Stock Performance Review on TherapeuticsMD and Three Other Healthcare Stocks

Stock Research Monitor: IDXX, PTN, and SNY

IDXX : 221.91 (-1.36%)
PTN : 0.94 (+2.17%)
Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs...

PTN : 0.94 (+2.17%)
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need...

PTN : 0.94 (+2.17%)
Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets.

PTN : 0.94 (+2.17%)
Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Homes 4 Rent (NYSE:AMH),...

DISCK : 25.94 (-0.92%)
VRTX : 156.57 (-0.67%)
NYT : 26.55 (+5.15%)
PTN : 0.94 (+2.17%)
AMH : 21.83 (-0.05%)
ETFC : 65.21 (unch)
Palatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs...

PTN : 0.94 (+2.17%)
Pre-Market Technical Scan on Healthcare Equities -- Atossa Genetics, Palatin Technologies, Quotient, and Avadel Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ATOS, PTN, QTNT, and AVDL which can be accessed for free by signing up to www.wallstequities.com/registration....

AVDL : 6.71 (-11.01%)
ATOS : 2.51 (-4.56%)
PTN : 0.94 (+2.17%)
QTNT : 8.93 (+0.11%)
Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need...

PTN : 0.94 (+2.17%)
AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide, which AMAG in-licensed from...

PTN : 0.94 (+2.17%)
AMAG : 21.13 (-3.10%)
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs...

PTN : 0.94 (+2.17%)
AMAG : 21.13 (-3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade PTN with:

Business Summary

Palatin Technologies, Inc is a development-stage medical technology companyinvolved in developing and commercializing products and technologies fordiagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling...

See More

Key Turning Points

2nd Resistance Point 0.98
1st Resistance Point 0.96
Last Price 0.94
1st Support Level 0.91
2nd Support Level 0.88

See More

52-Week High 1.59
Fibonacci 61.8% 1.12
Fibonacci 50% 0.98
Last Price 0.94
Fibonacci 38.2% 0.83
52-Week Low 0.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar